

Special Issue

Interventional Radiology: Towards Personalized Medicine

Message from the Guest Editor

The precision medicine initiative is having a far-reaching impact on prevention and treatment strategies that take individual patient variability into account. Interventional radiology (IR), in which imaging guidance is employed as a tool for both diagnosis and therapy, is tailored to specific cases. IR assumes a leading role in the transition toward precision medicine, particularly in image-guided biopsy techniques that enable the identification of the genomics and proteomics that drive tumor hyperproliferation, metastatic capabilities, and tumor angiogenesis mechanisms. This will help interventionalists to play a greater role in therapy selection; alter the need to use a specific drug and/or embolic material or device in the embolization procedure; and promote the use of novel image-guided techniques that can increase the technical and clinical success of procedures, reducing complications risk. This Special Issue aims to describe current advances in IR that do not merely improve the diagnosis and treatment of patients but promote IR as a specialty fully integrated with other disciplines, both clinical and surgical, and its role as a key tool in the decision-making process.

Guest Editor

Dr. Fabio Corvino

Vascular and Interventional Radiology Department, Cardarelli Hospital, I-80131 Naples, Italy

Deadline for manuscript submissions

20 June 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/185299

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).